Treatment of acute gouty arthritis in complex hospitalized patients with anakinra

Arthritis Care and Research

Volumn 65, Issue 8, 2013, Pages 1381-1384

  Ghosh, Pradipta ^a   Cho, Michael ^b   Rawat, Gurpreet ^b   Simkin, Peter A ^b   Gardner, Gregory C ^b  

^a KAISER PERMANENTE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COLCHICINE; INTERLEUKIN 1; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISONE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT;

ADULT; ADVERSE OUTCOME; AGED; ARTICLE; CLINICAL ARTICLE; COMORBIDITY; CREATININE CLEARANCE; DEMOGRAPHY; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GLOMERULUS FILTRATION RATE; GOUT; HOSPITAL PATIENT; HUMAN; INJECTION SITE REACTION; LEUKOPENIA; MALE; MEDICAL RECORD REVIEW; RETROSPECTIVE STUDY; SINGLE DRUG DOSE; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; ANTIRHEUMATIC AGENTS; ARTHRITIS, GOUTY; FEMALE; HOSPITALIZATION; HUMANS; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES;

EID: 84881334136     PISSN: 2151464X     EISSN: 21514658     Source Type: Journal    
DOI: 10.1002/acr.21989     Document Type: Article

References (15)

1. Pillinger MH, Rosenthal P, Abeles AM,. Hyperuricemia and gout: new insights into pathogenesis and treatment. Bull NYU Hosp Jt Dis 2007; 65: 215-21.
2. Cronstein BN, Terkeltaub R,. The inflammatory process of gout and its treatment. Arthritis Res Ther 2006; 8 Suppl: S3.
3. Martinon F, Petrilli V, Mayor A, Tardivel A, Tschopp J,. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 2006; 440: 237-41.
4. So A, De Smedt T, Revaz S, Tschopp J,. A pilot study of IL-1 inhibition by anakinra in acute gout. Arthritis Res Ther 2007; 9: R28.
5. McGonagle D, Tan AL, Shankaranarayana S, Madden J, Emery P, McDermott MF,. Management of treatment resistant inflammation of acute on chronic tophaceous gout with anakinra. Ann Rheum Dis 2007; 66: 1683-4.
6. McGonagle D, Tan AL, Madden J, Emery P, McDermott MF,. Successful treatment of resistant pseudogout with anakinra. Arthritis Rheum 2008; 58: 631-3.
7. Chen K, Fields T, Mancuso CA, Bass AR, Vasanth L,. Anakinra's efficacy is variable in refractory gout: report of ten cases. Semin Arthritis Rheum 2010; 40: 210-4.
8. Nocturne G, Ora J, Ea HK, Liote F,. Influenza A H1N1 and anakinra exposure in a patient with gout [letter]. Joint Bone Spine 2010; 77: 369-70.
9. Tran AP, Edelman J,. Interleukin-1 inhibition by anakinra in refractory chronic tophaceous gout. Int J Rheum Dis 2011; 14: e33-7.
10. Singh D, Huston KK,. IL-1 inhibition with anakinra in a patient with refractory gout. J Clin Rheumatol 2009; 15: 366.
11. Gratton SB, Scalapino KJ, Fye KH,. Case of anakinra as a steroid-sparing agent for gout inflammation. Arthritis Rheum 2009; 61: 1268-70.
12. Lin YH, Hsu HL, Huang YC, Lee M, Huang WY, Huang YC, et al. Gouty arthritis in acute cerebrovascular disease. Cerebrovasc Dis 2009; 28: 391-6.
13. So A, De Meulemeester M, Pikhlak A, Yucel AE, Richard D, Murphy V, et al. Canakinumab for the treatment of acute flares in difficult-to-treat gouty arthritis: results of a multicenter, phase II, dose-ranging study. Arthritis Rheum 2010; 62: 3064-76.
14. Schumacher HR Jr, Sundy JS, Terkeltaub R, Knapp HR, Mellis SJ, Stahl N, et al, on behalf of the 0619 Study Group. Rilonacept (Interleukin-1 Trap) in the prevention of acute gout flares during initiation of urate-lowering therapy: results of a phase II randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2012; 64: 876-84.
15. Anakinra [package insert]. Stockholm (Sweden): Swedish Orphan Biovitrum; 2012.